reports
- Geir Hiller Holom
Arctic Bioscience (Hold, TP: NOK10.00) - HeROPA readout expected in Q3
The company recently announced a fully recruited HeROPA trial and we expect 6-month data in Q3 2024. We have made minor revisions to our nutraceutical sales estimates and maintain our neutral view on the stock. We reiterate our HOLD and NOK10 target price.
- Geir Hiller Holom
Arctic Bioscience (Hold, TP: NOK10.00) - Patient recruitment is key co...
As communicated by management in H1, the HeROPA phase IIb clinical trial is active in all five planned countries participating in the trial. It had indicated a 6-month inclusion period of the 519 patients; we are approaching six months since the first patient was included (end-January 2023 in the UK), and have concerns that the recruitment period will continue for still some time. Following a further revision of timelines for the company’s pharmaceutical development efforts, we have cut our targ...
- Erik Cassel
PHO PHOTOCURE ASA
DEMANT DEMANT A/S
OSSR OSSUR HF.
NOVO B NOVO NORDISK A/S CLASS B
SOBI SWEDISH ORPHAN BIOVITRUM AB
GN GN STORE NORD A/S
ALK B ALK-ABELLO A/S CLASS B
CRAD B C-RAD AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
VICO VICORE PHARMA HOLDING AB
EKTA B ELEKTA AB CLASS B
COLO B COLOPLAST A/S CLASS B
HUM HUMANA AB
ATT ATTENDO
AZN ASTRAZENECA PLC
ONCO ONCOPEPTIDES AB
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
AMBU B AMBU A/S CLASS B
VITR VITROLIFE AB
MCAP MEDCAP
ULTI ULTIMOVACS
BOUL BOULE DIAGNOSTICS AB
IVACC INTERVACC AB
QLINEA Q LINEA AB
OSSD OSSDSIGN
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
IRLAB A IRLAB THERAPEUTICS
FLUO FLUOGUIDE AS
VIMIAN VIMIAN GROUP AB
LUND B H. LUNDBECK A/S
- Geir Hiller Holom
- Martin Arnell
- Miika Ihamaki
- Ole-Andreas Krohn
- Patrik Ling
- Adam Karlsson
- Jakob Lembke
- Adam Karlsson
SOBI SWEDISH ORPHAN BIOVITRUM AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
NANO NORDIC NANOVECTOR ASA
AZN ASTRAZENECA PLC
ONCO ONCOPEPTIDES AB
ULTI ULTIMOVACS
IVACC INTERVACC AB
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
IRLAB A IRLAB THERAPEUTICS
FLUO FLUOGUIDE AS
LUND B H. LUNDBECK A/S
- Adam Karlsson
- Erik Cassel
- Gonzalo Artiach
- Jakob Lembke
- Morten Larsen
NOVO B NOVO NORDISK A/S CLASS B
SOBI SWEDISH ORPHAN BIOVITRUM AB
CRAD B C-RAD AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
SANION SANIONA AB
NANO NORDIC NANOVECTOR ASA
HUM HUMANA AB
ATT ATTENDO
AZN ASTRAZENECA PLC
BIOVIC B BIOVICA INTERNATIONAL AB
ONCO ONCOPEPTIDES AB
BONEX BONESUPPORT HOLDING AB
MCAP MEDCAP
PCIB PCI BIOTECH HOLDING ASA
ULTI ULTIMOVACS
BOUL BOULE DIAGNOSTICS AB
IVACC INTERVACC AB
QLINEA Q LINEA AB
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
CLNK B CELLINK AB
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
IRLAB A IRLAB THERAPEUTICS
FLUO FLUOGUIDE AS
- Geir Hiller Holom
- Jesper Ingildsen
- Martin Arnell
- Martin Hoang Nguyen
- Niclas Gehin
- Ole Martin Westgaard
- Ole-Andreas Krohn
- Rune Majlund Dahl
- Steffen Evjen
- Geir Hiller Holom
Arctic Bioscience (Hold, TP: NOK17.00) - Holding zone
Although we believe the company has appealing long-term prospects, we see no potential share-price catalysts for the next 12 months. Following a change of analyst and on our lowered estimates for HRO350 (pharmaceutical business), we have downgraded the stock to HOLD (BUY) and cut our target price to NOK17 (60).
- Patrik Ling
Arctic Bioscience (Buy, TP: NOK60.00) - Q4 trading update
The company issued a planned trading update for Q4 on 18 February (the full report for 2021 is expected on 7 April). We have not updated our forecasts based on the trading update, since the company released only selected numbers. Sales for Q4 were slightly lower than we expected and the adj. EBITDA loss was also bigger. Guidance for 2022 was reasonably in line with our forecast. We reiterate our BUY and NOK60 target price.
- Adam Karlsson
- Jakob Lembke
- Marit Olsen
- Patrik Ling
Arctic Bioscience (Buy, TP: NOK60.00) - Change at the helm
On 14 January, Arctic Bioscience announced there would be a change of CEO during Q1. We see no drama – while the current CEO has been instrumental in taking the company to the current point, a new leg of the journey will commence in 2022e as the large phase II trial in psoriasis is set to be initiated. We reiterate our BUY and NOK60 target price.
- Adam Karlsson
- Erik Cassel
PHO PHOTOCURE ASA
DEMANT DEMANT A/S
OSSR OSSUR HF.
NOVO B NOVO NORDISK A/S CLASS B
SOBI SWEDISH ORPHAN BIOVITRUM AB
GN GN STORE NORD A/S
LUN H. LUNDBECK A/S
ALK B ALK-ABELLO A/S CLASS B
CRAD B C-RAD AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
ENZY ENZYMATICA AB
SANION SANIONA AB
NANO NORDIC NANOVECTOR ASA
EKTA B ELEKTA AB CLASS B
COLO B COLOPLAST A/S CLASS B
HUM HUMANA AB
ATT ATTENDO
AZN ASTRAZENECA PLC
BIOVIC B BIOVICA INTERNATIONAL AB
ONCO ONCOPEPTIDES AB
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
AMBU B AMBU A/S CLASS B
VITR VITROLIFE AB
MCAP MEDCAP
PCIB PCI BIOTECH HOLDING ASA
ULTI ULTIMOVACS
BOUL BOULE DIAGNOSTICS AB
IVACC INTERVACC AB
QLINEA Q LINEA AB
OSSD OSSDSIGN
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
CLNK B CELLINK AB
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
FLUO FLUOGUIDE AS
VIMIAN VIMIAN GROUP AB
- Patrik Ling
Arctic Bioscience (Buy, TP: NOK60.00) - Moving forward as planned
Arctic Bioscience reported H1 earnings on 26 August. The company is moving in the right direction and is on track to start the phase IIb trial in mild/moderate psoriasis in Q1 2022. Sales trends for its nutraceuticals are on track as is its new production facility in Ørsta. The burn rate was in line with previous guidance and the company reiterated all guidance comments for this year. We reiterate our BUY and NOK60 target price.
- Adam Karlsson
- Jakob Lembke
- Marit Olsen
- Viktor Sundberg
- Marit Olsen
- Rickard Anderkrans
- Viktor Sundberg
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.